Café

© 2026 Longbridge｜Terms of Service Privacy Policy

Alto Neuroscience

ANRO

36.3100.17% ( +0.060 )

Closed: Aug 25, 16:00:00 (EDT)

OverviewOverview OptionsOptions NewsNews PostsPosts FinancialsFinancials ForecastForecast ValuationValuation ShareholdersShareholders ProfileProfile

LongbridgeAI

Alto Neuroscience (NYSE:ANRO) Reaches New 1-Year High - Still a Buy?
Market Beat·16 hours ago
ANRO+0.17%
HC Wainwright Increases Alto Neuroscience (NYSE:ANRO) Price Target to $55.00
Market Beat·Aug 17 at 11:24 AM
ANRO+0.17%
Alto Neuroscience, Inc. Stock 12‑Month Price Target Raised to $37.56, Implies 16% Upside
TradingView·Aug 14 at 09:20 AM
ANRO+0.17%
Alto Neuroscience (NYSE:ANRO) Trading 8% Higher Following Earnings Beat
Market Beat·Aug 13 at 10:20 AM
ANRO+0.17%
Biotech Stocks At 52-Week Highs - BIVI +22%, XNCR, ANRO, HAE, ACAD
rttnews·Aug 13 at 03:30 AM
ANRO+0.17%ACAD+3.10%
ANRO: Precision psychiatry pipeline advances with biomarker-driven therapies and strong clinical data
Quartr·Aug 12 at 03:44 PM
ANRO+0.17%
Alto Neuroscience | 8-K: FY2026 Q2 Revenue: USD 0
Earnings Watch·Aug 12 at 03:36 PM
ANRO+0.17%
Alto Neuroscience posts corporate presentation outlining precision psychiatry drug pipeline, led by ALTO-207 in treatment-resistant depression
PUBT·Aug 12 at 03:29 PM
ANRO+0.17%
Alto Neuroscience Q2 net loss widens to $27.64 million; R&D expenses rise to $22.11 million
PUBT·Aug 12 at 03:05 PM
ANRO+0.17%
Alto Neuroscience (NYSE:ANRO) Sets New 52-Week High - Should You Buy?
Market Beat·Aug 12 at 01:00 PM
ANRO+0.17%
Biotech Stocks At 52-Week Highs - DCTH +22% On Q2 Results, ANRO, COAG, MNPR, NRIX
rttnews·Aug 7 at 05:33 AM
MNPR-0.48%ANRO+0.17%
Alto Neuroscience (NYSE:ANRO) Reaches New 52-Week High - What's Next?
Market Beat·Jul 31 at 09:00 AM
ANRO+0.17%
Alto Neuroscience Raises Capital to Advance ALTO-207
Tip Ranks·Jul 15 at 03:12 AM
ANRO+0.17%
Biotech Stocks Hit 52-Week Highs - TOI, IKT, ANRO, ELV, PRVA
rttnews·Jul 15 at 02:55 AM
ANRO+0.17%IKT0.00%
Alto Neuroscience Launches $93.9M Stock Offering at $26.48 in BofA-Led Underwriting
TradingView·Jul 14 at 05:13 AM
- Alto Neuroscience has entered an underwriting agreement to sell 3,776,436 shares of common stock at $26.48 per share in a registered direct offering. - The company expects to raise approximately $93.9 million, with proceeds aimed at supporting the accelerated clinical development of ALTO-207, including a planned Phase 3 trial. - Closing of this offering is anticipated on July 14, 2026, pending customary conditions.
ANRO+0.17%BAC+0.16%